FeesSafety
Pluang+

Horizon Technology Finance holds steady despite portfolio challenges and a 37% NAV discount.

Market News
29 Oct 2026, 16:15 WIB
Seeking Alpha
View Source
Neutral
Horizon Technology Finance holds steady despite portfolio challenges and a 37% NAV discount.

Horizon Technology Finance remains a hold as its portfolio growth and backlog provide a path forward, though improvements will take time. The stock trades at a 37% discount to its net asset value, reflecting significant portfolio challenges, including a $37 million net asset decline from Soli write-downs. Despite an attractive 18.4% dividend yield and ongoing special distributions, dividend coverage is thin and relies on spillover income. Management's strong capital position, backlog growth, and fee waivers support near-term stability, but risks remain due to higher interest rates and sector headwinds.

Horizon Technology Finance trades at a 37% discount to its net asset value, with an 18.4% dividend yield. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 29, 2026 20:12 WIB: out of 142 priced US Financial stocks, 102 rose and 35 fell. Notable movers include GLXY at USD 18.15 with a 4.92% decline and a typical hold time of 8 days, LYG at USD 5.25 with a 4.55% drop and 100% sell order activity, and BBVA at USD 23.95 with a 4.24% decrease and 100% buy order activity.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App